Pharmacists' Expanding Role in Managing Reflux and GORD

A series of clinical guidelines and articles outline the role of community pharmacists in assessing and managing symptoms of gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD). The resources detail a structured, stepwise approach combining lifestyle advice with pharmacological treatment and note an expanding scope of practice for pharmacists in some Australian jurisdictions.

Condition Overview and Prevalence

• Gastro-oesophageal reflux (GOR) is defined as the backward flow of stomach contents into the oesophagus.
• Gastro-oesophageal reflux disease (GORD) is diagnosed when reflux causes significant symptoms or potential damage to the oesophageal mucosa.
• A global meta-analysis cited in the guidelines suggests a pooled GORD prevalence of approximately 13.9%.

Pharmacist Role and Patient Assessment

Community pharmacists are frequently the first healthcare providers consulted by patients experiencing symptoms such as heartburn or regurgitation.

The guidelines emphasize structured patient history-taking to assess symptom frequency and severity. This assessment also serves to identify "alarm" symptoms that necessitate immediate medical referral.

These alarm symptoms include:

• Difficulty swallowing (dysphagia)
• Unintended weight loss
• Cardiac-like chest pain
• Severe abdominal pain
• Sudden onset of symptoms in a person aged 65 years or older
• Haematemesis (vomiting blood) or melaena (black, tarry stools)

The guidelines state that a formal diagnostic workup is not required for most patients presenting with typical symptoms and that an initial short trial of over-the-counter medicine is not considered to compromise patient safety.

Management Framework

Management is recommended to be patient-centered and based on symptom frequency and severity, integrating non-pharmacological and pharmacological strategies.

The guidelines highlight several lifestyle modifications with supporting evidence:

• Weight reduction for individuals with a high body mass index.
• Avoidance or reduction of tobacco smoking.
• Elevating the bedhead by 15–20 cm for nocturnal symptoms.
• Other commonly advised measures include avoiding late meals and reducing alcohol intake.

Four main over-the-counter (OTC) therapeutic classes are available in Australia for initial management:

1. Antacids: Provide rapid, temporary symptom relief by neutralizing stomach acid, with an onset of less than a minute and a duration of 20 minutes to 3 hours.
2. Alginates/Antacid-Alginate Combinations: Form a physical barrier or "raft" on stomach contents to reduce reflux, providing relief for several hours.
3. Histamine-2 Receptor Antagonists (H2RAs): Suppress gastric acid secretion, with an onset of about 60 minutes and effects lasting 4 to 12 hours.
4. Proton Pump Inhibitors (PPIs): Described as the most potent OTC acid suppressants. They irreversibly inhibit the proton pump, with effects lasting 15 to 24 hours after 1-3 days of treatment. OTC PPIs are typically taken once daily.

Stepwise Treatment Recommendations

Guidelines recommend a stepwise approach based on symptom frequency and severity.

• For mild, intermittent symptoms (e.g., 1–2 episodes weekly), initial options may include antacid-alginate combinations or H2RAs.
• For frequent or severe symptoms, an initial 4–8 week course of a standard-dose PPI is recommended, followed by step-down maintenance therapy to the lowest effective dose.
• Antacid-alginate therapy is noted for providing rapid relief and can be used adjunctively during PPI initiation or step-down to manage breakthrough symptoms.

Expanded Scope of Practice

The articles note that the scope of practice for Australian pharmacists is expanding in some jurisdictions. Following specific training, pharmacists in Queensland and New South Wales can prescribe medicines for specified conditions, including GORD, under clinical practice guidelines.

This expanded authority allows for extended initial PPI treatment periods beyond standard OTC limits and, in Queensland, provides access to Schedule 4 H2RAs.

Follow-up and Referral

Pharmacists are advised to schedule a follow-up review with patients after 2–4 weeks to assess treatment response and consider step-down therapy.

Medical referral is recommended for patients who do not respond to an initial short course of OTC acid-suppressive therapy or who present with any of the identified alarm symptoms.